TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14633536

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg metoclopramide
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg droperidol
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.13 mg/kg ondansetron
Number of subjects: 47

Group type: COMPARATOR
Intervention: 10 mL saline
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg metoclopramide
Number of subjects: 47
Study: 10717501

Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 16
Study: 8955972

Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg-1 and dexamethasone 4 mg (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Granisetron 40 micrograms.kg-1 and saline (Group S)
Number of subjects: 60
Study: 1485367

Group type: EXPERIMENTAL
Intervention: 300 or 600 mg of racemic ibuprofen (chronic dosing)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 300 or 600 mg of racemic ibuprofen (single doses)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chronic dosing of ibuprofen
Number of subjects: 45
Study: 3881033

Group type: EXPERIMENTAL
Intervention: Levobunolol 0.25%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Timolol 0.125%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levobunolol (overall)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Timolol (overall)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levobunolol and Timolol (both groups)
Number of subjects: 50
Study: 30600804

Group type: EXPERIMENTAL
Intervention: Noise stimulus on the fracture site with intensities of 0.1‐0.6 N and frequencies of 0.1‐50 Hz
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no noise stimulus)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 12
Study: 30113180

Group type: EXPERIMENTAL
Intervention: Routine Outcome Monitoring (ROM)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 170
Study: 27459418

Group type: EXPERIMENTAL
Intervention: Functional foot orthoses (FFO)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham orthosis
Number of subjects: 33
Study: 24710254

Group type: EXPERIMENTAL
Intervention: Endoscopic thyroidectomy (ET) via anterior chest wall approach (group A)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Traditional open surgery (group B)
Number of subjects: 320
Study: 23474349

Group type: EXPERIMENTAL
Intervention: 20mg Hyoscine N-butylbromide (HBB)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 20461028

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once daily for the first 7 weeks, increased to 120 mg for those with <30% pain reduction at week 7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18725858

Group type: EXPERIMENTAL
Intervention: Rheopheresis
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard therapy (intravenous corticosteroids or hemodilution)
Number of subjects: 240
Study: 15993254

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention of CBT and pharmacology
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (less burden of chronic medical illness)
Number of subjects: 232
Study: 12752317

Group type: EXPERIMENTAL
Intervention: 0.75 mg bid everolimus
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: 1.5 mg bid everolimus
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: Overall everolimus exposure
Number of subjects: 731
Study: 10337871

Group type: EXPERIMENTAL
Intervention: DG/EE formulation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: LN/EE formulation
Number of subjects: 21
Study: 7856893

Group type: EXPERIMENTAL
Intervention: Propofol/nitrous oxide
Number of subjects: 112

Group type: COMPARATOR
Intervention: Isoflurane/nitrous oxide
Number of subjects: 112
Study: 1827560

Group type: EXPERIMENTAL
Intervention: Intravenous fluorouracil and leucovorin
Number of subjects: 0
Study: 7408407

Group type: EXPERIMENTAL
Intervention: Oral bretylium tosylate (5 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous bretylium tosylate (5 mg/kg)
Number of subjects: 10
Study: 31170543

Group type: EXPERIMENTAL
Intervention: Vibrating mesh nebulizer (VMN)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Jet nebulizer (JN)
Number of subjects: 9
Study: 27296626

Group type: EXPERIMENTAL
Intervention: 15-week oral language programme delivered by trained teaching assistants
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 104
Study: 25306247

Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) - standard version
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) - individual feedback version
Number of subjects: 257

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 257
Study: 21816640

Group type: EXPERIMENTAL
Intervention: Low-dose ATN-224 (30 mg daily)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High-dose ATN-224 (300 mg daily)
Number of subjects: 47
Study: 21640687

Group type: EXPERIMENTAL
Intervention: Bedtime cilnidipine (10-20 mg/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cilnidipine (morning or bedtime)
Number of subjects: 43
Study: 18701184

Group type: EXPERIMENTAL
Intervention: Low-fat diet (Diet I)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (Diet II)
Number of subjects: 204
Study: 16530955

Group type: EXPERIMENTAL
Intervention: Prepulse + Pulse trials with 60, 120, and 240 ms prepulse-pulse intervals
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prepulse + Pulse trials with 60 and 120 ms prepulse-pulse intervals
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pulse-Alone trials
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prepulse + Pulse trials
Number of subjects: 19
Study: 12657911

Group type: EXPERIMENTAL
Intervention: Racemic reboxetine (6-month monotherapy)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Racemic reboxetine (therapeutic drug monitoring)
Number of subjects: 47
Study: 11084270

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% administered 30 minutes preoperatively
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ketorolac tromethamine 0.5% administered 1 day postoperatively
Number of subjects: 48
Study: 1384423

Group type: EXPERIMENTAL
Intervention: Vancomycin (1 g)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Teicoplanin (30 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy Volunteer Subjects (HVS) receiving vancomycin (1 g)
Number of subjects: 25
Study: 4050068

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aspirin-dipyridamole (ASA-D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anticoagulation with coumadine preparations (AC)
Number of subjects: 120
Study: 31880109

Group type: EXPERIMENTAL
Intervention: Critical care ultrasound oriented treatment
Number of subjects: 147

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fluid intake during salvage and optimization phases
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fluid intake during stabilization and de-escalation phases
Number of subjects: 147
Study: 30053670

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin with paclitaxel (Arm C)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin with pemetrexed (Arm D)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin with nab-paclitaxel (Arm E)
Number of subjects: 76
Study: 27411096

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) before PCI procedures
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 46
Study: 24591296

Group type: EXPERIMENTAL
Intervention: Nasal douche containing 9 mg of high molecular weight sodium hyaluronate plus saline solution
Number of subjects: 124

Group type: COMPARATOR
Intervention: Saline solution alone
Number of subjects: 124
Study: 22137609

Group type: EXPERIMENTAL
Intervention: Integrated pharmaceutical care programme (IPCP)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Normal follow-up (Control)
Number of subjects: 238
Study: 20413273

Group type: EXPERIMENTAL
Intervention: Preservation of the lobular branch of GAN (group C)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sacrifice of the main trunk of GAN (group A)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Preservation of the posterior-auricular branch (group B)
Number of subjects: 93
Study: 18568078

Group type: EXPERIMENTAL
Intervention: twice daily subcutaneous injections of leptin
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 16082018

Group type: EXPERIMENTAL
Intervention: Peak net joint moment (PM) during Work task
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Average net joint moment (AM) during Work task
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Net joint moment impulse (IP) during Work task
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Average net joint moment (AP) during Power task
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Net joint moment impulse (IM) during Power task
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All 6 measures during Work task
Number of subjects: 18
Study: 11860966

Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL) wear for 3 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (contralateral eye without SCL)
Number of subjects: 20
Study: 10068153

Group type: COMPARATOR
Intervention: Itraconazole 200 mg daily for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rifampicin 600 mg daily for 5 days
Number of subjects: 12
Study: 8882243

Group type: EXPERIMENTAL
Intervention: temazepam 20 mg plus ondansetron 8 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: temazepam 20 mg plus placebo
Number of subjects: 24
Study: 1733176

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg three times daily for 10 days
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 6395920

Group type: COMPARATOR
Intervention: Chemotherapy alone (Subgroup O)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen (Subgroup N)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Tamoxifen + Norethisterone (Subgroup NN)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Chemotherapy (Group I)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Chemotherapy (Group II)
Number of subjects: 223
Study: 31782009

Group type: EXPERIMENTAL
Intervention: Salvianolate
Number of subjects: 318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study: 28961557

Group type: EXPERIMENTAL
Intervention: Whole Slide Imaging (WSI)
Number of subjects: 1992

Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 1992

Group type: COMPARATOR
Intervention: Comparison of WSI and Microscopy
Number of subjects: 1992

Group type: EXPERIMENTAL
Intervention: WSI in endocrine pathology
Number of subjects: 1992

Group type: EXPERIMENTAL
Intervention: WSI in neoplastic kidney pathology
Number of subjects: 1992

Group type: EXPERIMENTAL
Intervention: WSI in urinary bladder pathology
Number of subjects: 1992

Group type: EXPERIMENTAL
Intervention: WSI in gynecologic pathology
Number of subjects: 1992
Study: 27211289

Group type: EXPERIMENTAL
Intervention: Patient centered pathology report
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard report
Number of subjects: 40
Study: 25543614

Group type: EXPERIMENTAL
Intervention: Role-play simulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lecture-based learning
Number of subjects: 32
Study: 22170790

Group type: EXPERIMENTAL
Intervention: Walking skill training program (12 sessions of weight-bearing activities)
Number of subjects: 68
Study: 19814835

Group type: EXPERIMENTAL
Intervention: Enteral supplement containing glutamine and antioxidants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 21
Study: 17211866

Group type: EXPERIMENTAL
Intervention: IA carboplatin with intravenous etoposide and cyclophosphamide
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IA methotrexate with intravenous etoposide and cyclophosphamide
Number of subjects: 38
Study: 16246231

Group type: EXPERIMENTAL
Intervention: 1-day high-dose quadruple therapy (esomeprazole 40 mg b.i.d., colloidal bismuth subcitrate 440 mg q.i.d., amoxicillin 2 g q.i.d., metronidazole 400 mg q.i.d. for 1 day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 7-day triple therapy (esomeprazole 20 mg b.i.d., clarithromycin 500 mg b.i.d., amoxicillin 1 g b.i.d. for 7 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1-day high-dose quadruple therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: 7-day triple therapy
Number of subjects: 80
Study: 12171809

Group type: EXPERIMENTAL
Intervention: Nortriptyline, 75 mg/d for 6 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9949712

Group type: EXPERIMENTAL
Intervention: Models used to convey spatial knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagrams used to convey spatial knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagrams with rich pictorial depth cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models viewed without access to depth cues
Number of subjects: 0
Study: 7758327

Group type: EXPERIMENTAL
Intervention: Histamine (0.1 mg/ml) administered via subcutaneous injections or by scratching at the site of patch tests
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control solution administered immediately before patch testing (0 hours) or 2x at 0 and 24 h
Number of subjects: 28
Study: 1869364

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 3 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg x 2 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg x 3 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 2 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg x 1 day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 1 day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Atabrine 1.2 g per case for males and 1.0 g per case for females (re-treatment after 3 months)
Number of subjects: 66
Study: 7164524

Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (without ultraviolet radiation)
Number of subjects: 13
Study: 31960188

Group type: EXPERIMENTAL
Intervention: Incorporating patient's information into surgical videos
Number of subjects: 130
Study: 31399143

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 27921200

Group type: EXPERIMENTAL
Intervention: Food, Health & Choices (FHC) intervention taught by trained FHC instructors
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Teacher interest
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fidelity
Number of subjects: 20
Study: 27210726

Group type: EXPERIMENTAL
Intervention: Online depression intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 58
Study: 24387891

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Asymptomatic comparison group
Number of subjects: 28
Study: 23785922

Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia (M)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Peri-articular injection (I)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Physiotherapy (P)
Number of subjects: 72
Study: 20329616

Group type: EXPERIMENTAL
Intervention: Corydalis composite (CDC) combined with methotrexate (MTX)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 76
Study: 17584432

Group type: EXPERIMENTAL
Intervention: Nursing care according to the Roper, Logan and Tierney Model
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 60
Study: 15641626

Group type: EXPERIMENTAL
Intervention: Once-daily budesonide administration
Number of subjects: 5998
Study: 12469466

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Mini‐cholecystectomy
Number of subjects: 181
Study: 9797101

Group type: EXPERIMENTAL
Intervention: 2‐mm microlaparoscope (MicroLap)
Number of subjects: 135

Group type: COMPARATOR
Intervention: 10‐mm standard laparoscope
Number of subjects: 135
Study: 7707626

Group type: EXPERIMENTAL
Intervention: Monovalent vaccine
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine
Number of subjects: 1006
Study: 2798994

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 48
Study: 87093

Group type: EXPERIMENTAL
Intervention: Aromatic retinoid ethyl ester (Ro 10‐9359)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31856991

Group type: EXPERIMENTAL
Intervention: Healon5 PRO OVD (bacterially derived sodium hyaluronate 2.3%)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Healon5 OVD (animal-derived sodium hyaluronate 2.3%)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Both OVDs
Number of subjects: 421
Study: 28340572

Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg, maximum 20 mg) and oral ketamine (3 mg/kg, maximum 50 mg) with 100% oxygen (MK)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg, maximum 20 mg) and oral ketamine (3 mg/kg, maximum 50 mg) with inhalational sevoflurane at a sedative dose (MKS)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MKS
Number of subjects: 27

Group type: COMPARATOR
Intervention: MK
Number of subjects: 27
Study: 24983382

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR)
Number of subjects: 120
Study: 23726660

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management intervention
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Cognitive coping strategies (acceptance and positive reframing)
Number of subjects: 325
Study: 23109026

Group type: EXPERIMENTAL
Intervention: Fetal liver‐derived hematopoietic stem cell transplantation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (5 ml of normal saline via intravenous route)
Number of subjects: 56
Study: 19535188

Group type: EXPERIMENTAL
Intervention: Forced euvolemic diuresis with saline, mannitol, and furosemide
Number of subjects: 92

Group type: COMPARATOR
Intervention: Saline hydration (control)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Overall (meta-analysis of 3 trials)
Number of subjects: 92
Study: 17405800

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVTA) injections
Number of subjects: 27
Study: 15082356

Group type: EXPERIMENTAL
Intervention: Patient controlled intranasal (PCIN) fentanyl
Number of subjects: 26

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 26
Study: 11438054

Group type: EXPERIMENTAL
Intervention: Confocal laser scanning tomography with clinical optic disk photographs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Confocal laser scanning tomography without clinical optic disk photographs
Number of subjects: 16
Study: 9549663

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Irbesartan 300 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Irbesartan 600 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Irbesartan 900 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8053583

Group type: COMPARATOR
Intervention: Soda lime as CO2 absorbent
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baralyme as CO2 absorbent
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (Soda lime and Baralyme)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baralyme
Number of subjects: 16
Study: 3072894

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pindolol 15 mg
Number of subjects: 21
Study: 31909884

Group type: EXPERIMENTAL
Intervention: Thinner-strut sirolimus-eluting bioresorbable scaffold (Firesorb)
Number of subjects: 45
Study: 30860411

Group type: EXPERIMENTAL
Intervention: SVW (same volume with both legs starting with the weaker leg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: DVW (double volume with the weaker leg starting with the weaker leg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: SVS (same volume with both legs starting with the stronger leg)
Number of subjects: 45
Study: 27353323

Group type: EXPERIMENTAL
Intervention: Heparin bridging
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Sub-pectoral location of ICD
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Previous stroke
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Upgrade from permanent pacemaker
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Clinically significant pocket haematoma
Number of subjects: 2500
Study: 26115880

Group type: EXPERIMENTAL
Intervention: LITE condition (one tai chi session twice weekly for 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PLUS condition (one tai chi session 3 times weekly for 12 weeks, followed by maintenance classes 1-2 times weekly for an additional 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LITE and PLUS conditions
Number of subjects: 60